Back to discover
Disease

Cutaneous melanoma

Late-stage therapeutic development
Also known as cutaneous (skin) melanoma, cutaneous melanoma (disease), malignant cutaneous melanoma, malignant ear melanoma+20 more

cutaneous (skin) melanoma, cutaneous melanoma (disease), malignant cutaneous melanoma, malignant ear melanoma, malignant lip melanoma, malignant lower limb melanoma, malignant melanoma (of skin), stage unspecified, malignant melanoma of ear and/or external auricular canal, malignant melanoma of skin, malignant melanoma of skin of lower limb, malignant melanoma of skin of trunk except scrotum, malignant melanoma of skin of upper limb, malignant melanoma of skin stage unspecified, malignant neck melanoma, malignant scalp melanoma, malignant trunk melanoma, malignant upper limb melanoma, melanoma (disease) of zone of skin, melanoma of skin, melanoma of the skin, skin melanoma, skin, melanoma, zone of skin melanoma, zone of skin melanoma (disease).

20
Clinical trials
12
Associated genes
8
Related proteins
Current focus
Melanocyte-stimulating hormone biologyPerforin-1 biologyTherapeutic development

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q4 2027.
Upcoming Milestones
Clinical Milestones9View all 9
Results posted 3
Results expected 5
Other updates 1
+1 more in the activity timeline below
Activity timeline9

Clinical trials

14 sponsors · 2 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
4
Late-stage
6
Completed
Late-stage studies

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2/3 · Active, not recruiting · National Cancer Institute (NCI)

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma

Phase 3 · Active, not recruiting · National Cancer Institute (NCI)

The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma

Phase 3 · Completed · Pfizer

PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Phase 3 · Terminated · Provectus Biopharmaceuticals, Inc.
Recently completed

A Phase II Study of Open Label Low Dose Ipilimumab in Combination With Pembrolizumab in Metastatic Melanoma Patients With Brain Metastases

Phase 2 · Completed · M.D. Anderson Cancer Center

Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma

Phase 2 · Completed · University of Kansas Medical Center

A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)

Phase 1/2 · Completed · Anaveon AG

Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma

Phase 2 · Completed · M.D. Anderson Cancer Center

A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 · Completed · National Cancer Institute (NCI)

The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma

Phase 3 · Completed · Pfizer

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

CDKN2A0.72MITF0.66OCA20.57MC1R0.56IRF40.54CYP1B10.54SLC45A20.51MX20.49FMN10.49RAC10.49MTAP0.48PLXNB20.47

Disease biology

8 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Melanocyte-stimulating hormone receptorvia MC1R0.56Ras-related C3 botulinum toxin substrate 1via RAC10.49Krueppel-like factor 4via KLF40.40Proto-oncogene tyrosine-protein kinase ROSvia ROS10.38Metabotropic glutamate receptor 5via GRM50.38Perforin-1via PRF10.37Baculoviral IAP repeat-containing protein 3via BIRC30.37Melanocyte protein PMELvia PMEL0.10

Reference

Authoritative identity, definition & identifiers.

Synonyms

cutaneous (skin) melanoma, cutaneous melanoma (disease), malignant cutaneous melanoma, malignant ear melanoma, malignant lip melanoma, malignant lower limb melanoma, malignant melanoma (of skin), stage unspecified, malignant melanoma of ear and/or external auricular canal, malignant melanoma of skin, malignant melanoma of skin of lower limb, malignant melanoma of skin of trunk except scrotum, malignant melanoma of skin of upper limb, malignant melanoma of skin stage unspecified, malignant neck melanoma, malignant scalp melanoma, malignant trunk melanoma, malignant upper limb melanoma, melanoma (disease) of zone of skin, melanoma of skin, melanoma of the skin, skin melanoma, skin, melanoma, zone of skin melanoma, zone of skin melanoma (disease)

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.